Analysis on the structure of top 100 pharmaceutical industry in China in 2015: the concentration ratio needs to be improved when the threshold of shortlisting is over 1.3 billion

Source: pharmaceutical economic daily July 15, 2016, "2015 top 100 list of Chinese pharmaceutical industry" was launched by pharmaceutical economic daily The selection activity was officially launched in January 2016 The selection committee conducted a five-month intensive data survey on enterprises registered in China In the "top 100 list of China's pharmaceutical industry" released this time, pharmaceutical machinery and veterinary drug manufacturing enterprises accounting for more than 90% of the revenue are not included in the statistical scope Meanwhile, multinational pharmaceutical enterprises in China are not included in this ranking, and they are not included in this ranking at the request of individual enterprises The proportion of chemical medicine industry has been reduced The sales revenue of five sub industries of China's pharmaceutical industry (chemical raw material industry, chemical pharmaceutical preparation industry, biological preparation industry, Chinese patent medicine industry and Chinese herbal medicine decoction piece industry) has increased from 363.3 billion yuan in 2005 to 2256.4 billion yuan in 2015 (monitored by Nanfang Institute), an increase of 6.2 times Among them, the proportion of chemical APIs and chemical preparations decreased from 31.7% and 31.3% to 20.7% and 30.8%, respectively The proportion of chemical APIs decreased significantly, while the proportion of Chinese patent medicine, biological preparations and Chinese Herbal Pieces increased from 25.2%, 8.7% and 3.1% to 27.6%, 13.5% and 7.5%, respectively In terms of profit, the total profit of the five sub industries of China's pharmaceutical industry in 2005 was 31 billion yuan, and the total profit in 2015 reached 229.3 billion yuan (monitored by Nanfang Institute), an increase of 7.4 times Among them, the proportion of profits of chemical API and Chinese patent medicine industry decreased from 20.9% and 31.1% to 15.1% and 28.3% respectively, and the proportion of other three sub industries increased The scale of top 100 pharmaceutical industry in China continues to expand, from 145.1 billion yuan in 2005 to 1045.8 billion yuan in 2015, an increase of 6.2 times In 2015, the growth rate of the top 100 pharmaceutical industry in China was 10.8% The scale range distribution of the listed enterprises is: in 2005, 55% of the top 100 pharmaceutical enterprises concentrated below 1 billion yuan, while in 2015, most of the top 100 pharmaceutical enterprises concentrated between 2 billion yuan and 5 billion yuan (42 enterprises) In 2010, five enterprises broke the 10 billion yuan mark for the first time By 2015, there were 12 enterprises, including five enterprises with more than 20 billion yuan, and 23 enterprises with 5-10 billion yuan The top 100 pharmaceutical companies are expanding rapidly In 2005, the threshold for the top 100 pharmaceutical enterprises in China was only 480 million yuan, and then increased year by year In 2013, due to the adjustment of the selection rules, the list did not include foreign-funded enterprises, so the threshold dropped to 930 million yuan In 2015, the threshold for the top 100 pharmaceutical enterprises reached 1.3 billion yuan, up 12.0% from 2014 , which also reflects the overall rapid growth of domestic mainstream pharmaceutical enterprises Among them, the rapid rise of small and medium-sized enterprises from the 100th place shows this feature, for example, Lu kangchenxin pharmaceutical, the 100th place in 2008, jumped to 82 in 2015, and Zhejiang Huahai pharmaceutical, the 100th place in 2010, jumped to 49 in 2015 In terms of the regional distribution of the number of top 100 enterprises in the eastern region (by economic geography), in 2015, there were 64 top 100 enterprises in the eastern region, down 9 from 2005 Among them, in 2005, Jiangsu Province had the largest number (15), while in 2015, Guangdong Province and Shandong Province had the largest number (11) In 2015, the number of top 100 enterprises in the central and western regions was 23 and 13 respectively The proportion of top 100 enterprises in the industry (the data shows that the industrial and commercial consolidated sales of top 100 enterprises in each province accounts for the proportion of sales of five sub industries) In 2005, 28.5%, 6.8% and 3.7% in the East, middle and west respectively, and in 2015, 25.3%, 7.6% and 4.0% respectively Among them, the proportion of top 100 enterprises in Shanghai is the highest, reaching 5.5% In 2015, the concentration of the top 100 pharmaceutical companies increased gradually The concentration of the top 100 pharmaceutical companies in China was 46.3%, 7.4 percentage points higher than that in 2005 and 0.5 percentage points higher than that in 2014 Although there is still a certain gap between this and the target of "the 12th Five Year Plan" to achieve 50% of the top 100 pharmaceutical industry, with the acceleration of industrial integration, especially the consistency evaluation of generic drugs and the two vote system driving the industry reshuffle, the enterprise merger and reorganization efforts are strengthened, and it is believed that the concentration of the top 100 pharmaceutical industry will be further improved in 2016 Among the leading groups, in 2015, the concentration of the top 10 pharmaceutical companies reached 21.1%, accounting for about 50% of the top 100 enterprises, and the concentration of the top 20 pharmaceutical companies reached 28.3% Among the top 100 pharmaceutical enterprises in 2015, there were 53 chemical enterprises, 39 traditional Chinese medicine enterprises and 4 biological products enterprises Compared with 2005 and 2010, the number of chemical enterprises decreased, and the number of traditional Chinese medicine enterprises and biological products enterprises increased In terms of the position of top 100 enterprises in the corresponding sub industries, the top 100 enterprises of traditional Chinese medicine account for the highest proportion of sales, accounting for 45.8%; the profit accounts for 30.7%, 39.1% and 6.3% of chemical medicine industry, traditional Chinese medicine industry and biological preparation industry respectively Some enterprises are far ahead of the industry in 2015 The average growth of sales revenue and profit of the five pharmaceutical sub industries is 9.6% and 10.7% respectively Some of the top 100 enterprises are far ahead of the industry average In 2015, the sales revenue of Jiuzhitang increased rapidly, reaching 91%, and the sales revenue of 6 enterprises increased by more than 50% In terms of net interest rate growth, 5 enterprises exceeded 100% Since 2011, the number of Listed Companies in the top 100 pharmaceutical enterprises in China has exceeded 70, which has remained relatively stable in recent years In 2015, there were 78 listed companies among the top 100 pharmaceutical enterprises, an increase of 1 over 2014 The number of subsidiaries included in the scope of merger by listed companies has exceeded 1100, reaching 1150, and the pace of capital operation of top 100 enterprises has gradually accelerated In the past decade, the proportion of sales revenue of Listed Companies in the top 100 enterprises has increased year by year, reaching 79.4% in 2015, an increase of 29.3 percentage points over 2006 There are 8 listed companies in the top 10 of the top 100, with sales revenue accounting for nearly 40% of the top 100